

Washington University School of Medicine

Digital Commons@Becker

Open Access Publications

2021

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

Purushothaman Jambulingam

ICMR-Vector Control Research Centre, Puducherry, India

Vijesh Sreedhar Kuttiatt

ICMR-Vector Control Research Centre

Kaliannagounder Krishnamoorthy

ICMR-Vector Control Research Centre, Puducherry, India

Swaminathan Subramanian

ICMR-Vector Control Research Centre, Puducherry, India

Adinarayanan Srividya

ICMR-Vector Control Research Centre, Puducherry, India

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

See next page for additional authors

Recommended Citation

Jambulingam, Purushothaman; Kuttiatt, Vijesh Sreedhar; Krishnamoorthy, Kaliannagounder; Subramanian, Swaminathan; Srividya, Adinarayanan; Raju, Hari Kishan K.; Rahi, Manju; Somani, Roopali K.; Suryaprakash, Mallanna K.; Dwivedi, Gangeshwar P.; and Weil, Gary J., "An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India." .. . (2021). https://digitalcommons.wustl.edu/open_access_pubs/9999

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Purushothaman Jambulingam, Vijesh Sreedhar Kuttiatt, Kaliannagounder Krishnamoorthy, Swaminathan Subramanian, Adinarayanan Srividya, Hari Kishan K. Raju, Manju Rahi, Roopali K. Somani, Mallanna K. Suryaprakash, Gangeshwar P. Dwivedi, and Gary J Weil

This document is a placeholder for the accepted manuscript or final pdf of the following publication:

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

Purushothaman Jambulingam¹, Vijesh Sreedhar Kuttiatt^{1*}, Kaliannagounder Krishnamoorthy¹, Swaminathan Subramanian^{1*}, Adinarayanan Srividya¹, Hari Kishan K. Raju¹, Manju Rahi², Roopali K. Somani³, Mallanna K. Suryaprakash⁴, Gangeshwar P. Dwivedi⁵, Gary J. Weil⁶

¹ ICMR-Vector Control Research Centre, Indira Nagar, Puducherry, India.

² Indian Council of Medical Research, Ansari Nagar, New Delhi, India.

³ Dept of Clinical Pharmacology & Therapeutics, Nizams Institute of Medical Sciences, Hyderabad, India

⁴ District Vector-Borne Disease Control Programme, Yadgiri, Karnataka, India

⁵ State Surveillance Medical officer WHO (Retd.), Yamuna Vihar, ward No 5, Paonta sahib, Himachal Pradesh, India

⁶ Washington University School of Medicine, St. Louis, Missouri, United States of America